POPULARITY
28 episodes with axspa
15 episodes with axspa
5 episodes with axspa
12 episodes with axspa
5 episodes with axspa
5 episodes with axspa
5 episodes with axspa
5 episodes with axspa
3 episodes with axspa
Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.
From Pain to Wellness in PsA Secukinumab vs Ustekinumab in PsA Izokibep: still enthused about enthesitis? Using Digital Apps to Modify Pain in axSpA
Revised Classification Criteria in axSpA https://www.youtube.com/watch?v=voFJrQo1ANU NSAID Addition Helps the Spine but not the Hips https://www.youtube.com/watch?v=wTKMC1MTwpE Biomarker Discovery in axSpA https://www.youtube.com/watch?v=X8Sc_3oBSVA Sexual Function in axSpA https://www.youtube.com/watch?v=r4_Nsh7e_oo Coping Strategies in axSpA https://www.youtube.com/watch?v=z9KdNuOu4nI "ROC-SpA Study" https://www.youtube.com/watch?v=kIEN39XRsSM Why do patients stay in clinical trials? https://www.youtube.com/watch?v=pVIBoN0jO2o What to do after first TNR failure in axSpA? https://www.youtube.com/watch?v=PVSyq_Y5-PE
From Pain to Wellness in PsA IL-2 Therapy in SLE? Maybe Sexual Function in axSpA "Fact or Fiction: Trinetics Research at ACR" CD1/BCMA Dual Targeting: One too many targets in SLE Hydroxychloroquine Blood Levels The Great Debate: AI in Rheumatology Coping Strategies in axSpA "What to do After First TNR Failure in axSpA"
Spondyloarthritis: The CLASSIC Study "Leftover Pain in Inflammatory Arthritis" NeuroImmune Modulation in RA: Results of the RESET RA Trial Change it or Keep it? TNF in Axial SpA Perspectives on CAR T Therapy Addressing Lupus Nephritis Early Addressing Lupus Nephritis Aggressively CAR-T: The Future Biomarker Discovery in axSpA Another Specialized Biomarker in PsA Revised Classification Criteria in axSpA
GDF-15: How Depression is Related to Lung Disease in RA What Can we do About Chronic Pain? What's the latest in PsA? What to do after first TNR failure in axSpA?
Diagnostic Delays in PsA: A Radiographic Perspective Late-Breaking Trials in axSpA and PsA New Approaches to Therapy in PsA
Catching AxSpA Early: Closing the Diagnostic Gap Early Peripheral SpA: Is it okay to stop treatment sometimes? Difficult to Manage axSpA Tofacitinib in AxSpA in Developing Countries Late-Breaking Trials in axSpA and PsA Durability and Safety of Bimekizumab Biologics Improve Sexual Function in axSpA Multidimensional Pain inventory in Axial SpA Spondyloarthritis: The CLASSIC Study Change it or Keep it? TNF in Axial SpA "Leftover Pain in Inflammatory Arthritis"
Off the Shelf: CAR-T Combining CAR-T with CAR-Treg All in One Tapering in SELECT GCA: Steroids are the Problem Diagnostic Delays in PsA: A Radiographic Perspective Late-Breaking Trials in axSpA and PsA New Approaches to Therapy in PsA PRED-SAFE: Chronic Prednisone Use PsA and Brain Fog CAR-T Therapy: Where is it Heading?
A Nose for Vasculitis: ENT Manifestations in ANCA-Associated Disease Tofacitinib in AxSpA in Developing Countries Specialized Biomarkers in PsA B Cell Depletion: Check the Lymph Node GLP-1 and SGLT-2: Treatments Too Good to Ignore? Nerandomilast for ILD PsA: Impact of Sex Cellular Biomarkers of Rheumatoid Arthritis Using AI and LLMs in Qualitative Data Belimumab Before or After Immunosuppressant Do Patients with Rheumatic Diseases 'Weather' the Storm? AI in Fellow Recruitment: A New Dawn in Medical Education?
Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025
Listen or watch along as we dive into updates on axial spondyloarthritis (axSpA) treatments and 'The 2025 British Society for Rheumatology guideline for treatment of axial Spondyloarthritis with biologic and targeted synthetic DMARDs'.In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks with Professor Raj Sengupta, Consultant rheumatologist and Lead Consultant for Axial Spondyloarthritis at the RNHRD, RUH Bath about changes to axSpA treatments since our first series in 2020. Useful Links:BSR GuidelineNational Axial Spondyloarthritis SocietyInhealthcare Connect further with us:Have questions or thoughts about our information Podcast library? Interested in joining BIRDs patient research panel? Email Mel at ppe@birdbath.org.ukBe sure to subscribe, rate, and review the podcast to help us continue sharing information that matters!Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases.Please visit the BIRD website to sign up for news.
Listen or watch along as we dive into updates on axial spondyloarthritis (axSpA) treatments and 'The 2025 British Society for Rheumatology guideline for treatment of axial Spondyloarthritis with biologic and targeted synthetic DMARDs'.In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks with Professor Raj Sengupta, Consultant rheumatologist and Lead Consultant for Axial Spondyloarthritis at the RNHRD, RUH Bath about changes to axSpA treatments since our first series in 2020. Useful Links:BSR GuidelineNational Axial Spondyloarthritis SocietyInhealthcare Connect further with us:Have questions or thoughts about our information Podcast library? Interested in joining BIRDs patient research panel? Email Mel at ppe@birdbath.org.ukBe sure to subscribe, rate, and review the podcast to help us continue sharing information that matters!Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases.Please visit the BIRD website to sign up for news.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.
Listen or watch along as we dive into the changing landscape of axial spondyloarthritis (axSpA) diagnosis.In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks with Dr Tom Williams, Consultant rheumatologist and Education Lead at the RNHRD, RUH Bath about changes to the axSpA diagnosis process since our first series in 2020. From persistent delays and the different experiences of women, to new tools like the NASS Playbook, PRIMIS pop-up, and Symptom Checker, we look at what's helping clinicians and patients. We also touch on non-radiographic axSpA, the growing role of MRI, blood markers, and how to approach cases that aren't clear-cut — before rounding off with some patient questions. Useful Links:National Axial Spondyloarthritis SocietyRoyal National Hospital for Rheumatic Diseases, RUH BathConnect further with us:Have questions or thoughts about our information Podcast library? Interested in joining BIRDs patient research panel? Email Mel at ppe@birdbath.org.ukBe sure to subscribe, rate, and review the podcast to help us continue sharing information that matters!Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases.Please visit the BIRD website to sign up for news.
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA' and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab'.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.
Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.
Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they guide you through what they are most looking forward to in RA, PsA, and axSpA at EULAR 2025, so that you can better plan your time at what will be a busy and exciting congress.
In this episode, we examine the evaluation of pain in patients with chronic inflammatory arthritis, with particular attention to spondyloarthritis and its clinical overlap with fibromyalgia. We explore why some patients continue to report persistent pain despite well-controlled inflammation, and the importance of distinguishing between active inflammatory disease and centralized pain syndromes such as fibromyalgia. Join us as we unpack the diagnostic nuances that can significantly impact patient care.
Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA. In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cycling with other TNF inhibitors, and the second investigates long-term safety of bimekizumab in adult patients with axSpA or PsA.
Join Gozde and Oliver as they talk with Prof. Denis Poddubnyy about the ASAS consensus definition of difficult-to-manage axSpA.Get a behind-the-scenes look at how this definition was developed, the challanged faced, and what it means for clinical practice and research.
In this episode, we're joined by Dr. Atul Deodhar, a leading expert in the field of Axial Spondyloarthritis (AxSpA). Dr. Deodhar shares insights from his groundbreaking research on the pathophysiology, diagnosis, and management of AxSpA, particularly focusing on the efficacy and safety of IV secukinumab. We dive deep into his study, INVIGORATE-1, exploring the methods behind it, including the use of Interactive Response Technology, and the primary and secondary endpoints that shed light on this treatment's impact. We also discuss the latest data on patient preferences for subcutaneous versus intravenous immunomodulators and the implications of these findings. Tune in for an informative and engaging conversation that blends cutting-edge science with thoughtful reflections on patient care.
In this episode, we dive into the cutting-edge advancements presented by Dr. Christopher T. Ritchlin at Convergence 2024, where he shed light on the promising research set to transform the field of rheumatology. Join us as we break down key insights from one of the field's leading experts, exploring the future of precision medicine, the role of TRBV9 cells in axSpA, the impact of sex differences on PsA, and the potential of urinary biomarkers in Lupus Nephritis. Tune in for a fascinating discussion on what's next in rheumatology.
Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA. In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy of Bimekizumab in axSpA patients with 5-year results from the BE-AGILE study and its OLE, and the 2-year results from BE-MOBILE 1 and 2.
Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program:https://bit.ly/4gkTzSv
Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program: bit.ly/4gkTzSv
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.
In this episode, we explore the findings of a groundbreaking study analyzing opioid treatment trends for adults with and without systemic autoimmune and inflammatory rheumatic diseases (SARDs) from 2006 to 2019. The study, based on national data from the United States, sheds light on how individuals with conditions like rheumatoid arthritis, lupus, and ankylosing spondylitis are impacted by opioid use compared to the general population.
A New ACR Anti IL-17 on Entheseal Biopsy in PsA axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure Best Things I Saw Today in PsA Cycling vs Switching after TNFi Failure in axSpA Improvements in Pain and Fatigue in Bimekizumab Long-term Safety Profile of Bimekizumab in axSpA and PsA Sonelokimab in PsA: Phase 2 Data Treating SpA
A New ACR Apremilast Benefits and Risks in PsA Best Things I Saw Today in PsA Bimekizumab in PsA Showed Sustained Reductions in Disease Impact Biologic Monotherapy vs Combination with cDMARDs in PsA Do TNFis and JAKis Prevent Cancer!? Improvements in Pain and Fatigue in Bimekizumab Long-term Safety Profile of Bimekizumab in axSpA and PsA Potential Impact of Weight Loss Drugs in Rheumatic Diseases Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis PsA Potpourri PsA Ultrasound Updates PsA: Impact of Sex Sex Differences in Psoriatic Arthritis The Psoriatic March: PsA before PsO Apremilast in PsA: Results from Mosaic Trial Anti IL-17 on Entheseal Biopsy in PsA
A New ACR Assessing ASAS Criteria: CLASSIC Study Results Assessment and management of axSpA Assessment of axSpA Carotid Doppler Ultrasound Screening in Axial SpA Cycling vs Switching after TNFi Failure in axSpA Defining Difficult to Manage axSpA Difficult to manage AxSpA DISH in SpA Gender Differences in AxSpA Highlights in axSpA Hot Topics in axSpA Long-term Safety Profile of Bimekizumab in axSpA and PsA Machine Learning for Predicting Flares in axSpA Precision Immunotherapy in Axial SpA PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Treating SpA What is a Positive MRI in Spondyloarthritis? axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure
Control RA, Build Stronger Bones:Dr. Jiha Lee talks with Dr. Rachel Elam Hold or continue JAKi and IL-17 when receiving COVID boosters?:Dr. Bella Mehta Long-term Safety Profile of Bimekizumab in axSpA and PsA:Dr. Philip Mease Navigating Rheumatology Care in Humanitarian Crisis Settings:Dr. Antoni Chan talks with Dr. Martha Dhzhus RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?:Dr. Eric Dein Sex Differences in Psoriatic Arthritis:Dr. Catherine Bakewell Single v Double Lung Transplants for Disease-related ILD:Dr. Eric Dein talks with Dr. Harry Hurley Sonelokimab in PsA: Phase 2 Data:Dr. Philip Mease Treating SpA:Dr. Marina Magrey
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.
Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA
Tune in this week for the final episode of our three part AxSpA series. Dr Moorthy covers everything from exercise to etanercept, and gives all of us yet another good reason to go swimming!
Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the results of a Phase 3 trial on upadacitinib in nr-axSpA and the clinical outcomes of certolizumab pegol treatment in nr-axSpA stratified by baseline MRI and CRP status.
Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they review their top sessions in RA, PsA, and axSpA from EULAR 2024, providing insight into how these data will shape clinical practice going forward.
Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab
When disease strikes, time becomes a critical resource our patients cannot afford to waste. For those with axial spondyloarthritis (axSpA), an inordinate amount of time often goes by before a proper diagnosis is made, resulting in delays for crucial treatments to be rendered. The reasons for this delay in diagnosis, particularly among those with axSpA are diverse, complicated and not well-understood. Our guest, Dr. Gregory McDermott, attempted to better understand this diagnostic delay with his study: Factors Associated With Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability in hopes that we may begin answering these challenges with solutions.
Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they guide you through their top selections in RA, PsA, and axSpA at EULAR 2024, so that you can better plan your time at what will be a busy and exciting congress.
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-world clinical context.
Recent research indicates that those who suffer from AxSpA may have some hope in protecting against events of Uveitis! Dr. Katie Bechman, first author Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta-Analysis, explains her team's research findings and how they came to this exciting conclusion!
Join our expert panel as they discuss the role of Janus kinase (JAK) inhibitors in the treatment of axial spondyloarthritis (axSpA). Credit available for this activity expires: 4/24/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000707?ecd=bdc_podcast_libsyn_mscpedu
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs.
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab.
Bimekizumab in Active AS_ 5 Year Study Deep Neural Networks and Radiographic Progression in AxSpA Difficult to Treat axSpA From AS Patient to Rheumatologist Imaging Updates in SpA INVIGORATE-1 Study_ IV Secukinumab for Treatment of Active axSpA Monitoring the Effect of Therapy with a...Smart Watch_ Overlap of Inflammatory and Degenerative Features in Radiographic axSpA People with AxSpa Need More Sleep Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA SpA Insights_ New Therapies Teledidactic vs On Campus Training in Musculoskeletal Ultrasound Treatments in SpA Undiagnosed IBD in AxSpA Using Telemedicine to Improve Diagnosis of AxSpA
© 2020-2025 Ivy Podcast Discovery LLC
